Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

PURPOSE: About 40–60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III trial, investigated the role of cochlear-sparing IMRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Nutting, Christopher M., Morden, James P., Beasley, Matthew, Bhide, Shreerang, Cook, Audrey, De Winton, Emma, Emson, Marie, Evans, Mererid, Fresco, Lydia, Gollins, Simon, Gujral, Dorothy, Harrington, Kevin, Joseph, Mano, Lemon, Catherine, Luxon, Linda, van den Blink, Qurrat, Mendes, Ruheena, Miah, Aisha, Newbold, Kate, Prestwich, Robin, Robinson, Martin, Sanghera, Paul, Simpson, Joanna, Sivaramalingam, Muthiah, Srihari, Narayanan Nair, Sydenham, Mark, Wells, Emma, Witts, Stephanie, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202674/
https://www.ncbi.nlm.nih.gov/pubmed/30286418
http://dx.doi.org/10.1016/j.ejca.2018.08.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202674/
https://www.ncbi.nlm.nih.gov/pubmed/30286418
http://dx.doi.org/10.1016/j.ejca.2018.08.006

Ejemplares similares